A Weak Neutralizing Antibody Response to Hepatitis C Virus Envelope Glycoprotein Enhances Virus Infection

We have completed a phase 1 safety and immunogenicity trial with hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, with MF59 adjuvant as a candidate vaccine. Neutralizing activity to HCV genotype 1a was detected in approximately 25% of the vaccinee sera. In this study, we evaluated vaccinee...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Meyer, Keith, Banerjee, Arup, Frey, Sharon E., Belshe, Robert B., Ray, Ranjit
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2011
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3161815/
https://ncbi.nlm.nih.gov/pubmed/21887300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0023699
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars